Desloratadine mitigates hepatocellular carcinoma in rats: Possible contribution of TLR4/MYD88/NF-κB pathway
Toxicology and Applied Pharmacology · 2025
DOI: 10.1016/j.taap.2024.117202 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxicology and Applied Pharmacology, 2025. Verfasst von Heba A Bahriz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Hauptthemen laut MEDLINE: Toll-Like Receptor 4, Myeloid Differentiation Factor 88, Loratadine, NF-kappa B. Die Arbeit nennt 67 Literaturangaben. Gefördert von: Mansoura University.
Abstract (Originalsprache)
Chemotherapeutic medication-induced systemic toxicity makes cancer treatment less effective. Thus, the need for drug repurposing, which aids in the development of safe and efficient cancer therapies, is urgent. The primary goal of this research was to assess desloratadine hepatoprotective abilities and its capacity to attenuate TLR4/MyD88/NF-κB inflammatory pathway in hepatocellular carcinoma (HCC) induced by thioacetamide (TAA). Male Sprague Dawely rats received TAA injections (200 mg/kg, i.p., 2 times/week) for 16 weeks. To confirm the development of HCC, liver function biomarkers and histopathological analysis were evaluated. Desloratadine (5 mg/kg, p.o.) was administered to rats in 2 treatment groups; HCC + DES 1 group received desloratadine with TAA for 1 month from week 13-16, HCC + DES 2 group received desloratadine with TAA for 2 months from week 9-16. Chronic TAA administration resulted in considerable overexpression of the profibrogenic cytokine TGF-β and elevation in protein expression of NF-κB besides levels of TLR4, MyD88, TRAF6, TAK1 and IL-1β. Desloratadine administration showed a significant improvement in liver function tests, as well as an increase in tissue antioxidant enzymes and an improvement in the liver's histopathological features. Collectively, desloratadine through modulating TLR4/MyD88/TRAF6/TAK1/NF-κB and acting as an antioxidant, is a promising treatment for HCC induced by TAA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt. Electronic address: rania200582@yahoo.com.
Förderung
- Mansoura University
Zitieren
APA
Bahriz, H. A., Abdelaziz, R. R., & El-Kashef, D. H. (2025). Desloratadine mitigates hepatocellular carcinoma in rats: Possible contribution of TLR4/MYD88/NF-κB pathway. Toxicology and Applied Pharmacology. https://doi.org/10.1016/j.taap.2024.117202
Vancouver
Bahriz HA, Abdelaziz RR, El-Kashef DH. Desloratadine mitigates hepatocellular carcinoma in rats: Possible contribution of TLR4/MYD88/NF-κB pathway. Toxicology and Applied Pharmacology. 2025. doi:10.1016/j.taap.2024.117202
BibTeX
@article{Bahriz2025,
author = {Bahriz, Heba A and Abdelaziz, Rania R and El-Kashef, Dalia H},
title = {Desloratadine mitigates hepatocellular carcinoma in rats: Possible contribution of TLR4/MYD88/NF-κB pathway},
journal = {Toxicology and Applied Pharmacology},
year = {2025},
doi = {10.1016/j.taap.2024.117202}
}
EUVIMED